Advertisement
Screener

ATOSSA THERAPEUTICS, INC. (ATOS) Increase (Decrease) in Prepaid Expense and Other Assets

2.8 / 5 stars · 68/120 Roast Me

ATOSSA THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets

ATOSSA THERAPEUTICS, INC. (ATOS) reported Increase (Decrease) in Prepaid Expense and Other Assets of $665.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-07

  • ATOSSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$34.00K.
  • ATOSSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $699.00K, a 155.11% increase year-over-year.
  • ATOSSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $548.00K, a 154.88% increase year-over-year.
  • ATOSSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$495.00K.
  • ATOSSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$37.00K.
  • ATOSSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$997.00K.
  • ATOSSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.00M.
  • ATOSSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$180.00K.
Period endIncrease (Decrease) in Prepaid Expense and Other Assets 3 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 monthIncrease (Decrease) in Prepaid Expense and Other Assets 9 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 month as first filed
2026-06-30-$34.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
$665.00K
10-Q · filed 2026-08-07
$1.21M
derived: sum of 3 quarters · filed 2026-08-07
$718.00K
derived: sum of 4 quarters · filed 2026-08-07
2026-03-31$699.00K
10-Q · filed 2026-05-08
$1.25M
derived: sum of 2 quarters · filed 2026-05-08
$752.00K
derived: sum of 3 quarters · filed 2026-05-08
$388.00K
derived: sum of 4 quarters · filed 2026-08-07
2025-12-31$548.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$53.00K
derived: sum of 2 quarters · filed 2026-03-25
-$311.00K
derived: sum of 3 quarters · filed 2026-08-07
-$37.00K
10-K · filed 2026-03-25
2025-09-30-$495.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$859.00K
derived: sum of 2 quarters · filed 2026-08-07
-$585.00K
10-Q · filed 2025-11-12
-$370.00K
derived: sum of 4 quarters · filed 2026-08-07
2025-06-30-$364.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
-$90.00K
10-Q · filed 2026-08-07
$125.00K
derived: sum of 3 quarters · filed 2026-08-07
$88.00K
derived: sum of 4 quarters · filed 2026-08-07
2025-03-31$274.00K
10-Q · filed 2026-05-08
$489.00K
derived: sum of 2 quarters · filed 2026-05-08
$452.00K
derived: sum of 3 quarters · filed 2026-05-08
-$174.00K
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$215.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$178.00K
derived: sum of 2 quarters · filed 2026-03-25
-$448.00K
derived: sum of 3 quarters · filed 2026-03-25
-$997.00K
10-K · filed 2026-03-25
2024-09-30-$37.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$663.00K
derived: sum of 2 quarters · filed 2025-11-12
-$1.21M
10-Q · filed 2025-11-12
-$1.67M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$626.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$1.18M
10-Q · filed 2025-08-12
-$1.64M
derived: sum of 3 quarters · filed 2025-08-12
-$2.27M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$549.00K
10-Q · filed 2025-05-13
-$1.01M
derived: sum of 2 quarters · filed 2025-05-13
-$1.64M
derived: sum of 3 quarters · filed 2025-05-13
-$1.66M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$462.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25
-$1.09M
derived: sum of 2 quarters · filed 2025-03-25
-$1.11M
derived: sum of 3 quarters · filed 2025-03-25
-$1.00M
10-K · filed 2025-03-25
-$261.00K
10-K · filed 2024-04-01
2023-09-30-$633.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$650.00K
derived: sum of 2 quarters · filed 2024-11-12
-$542.00K
10-Q · filed 2024-11-12
2023-06-30-$17.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
$91.00K
10-Q · filed 2024-08-12
2023-03-31$108.00K
10-Q · filed 2024-05-13
2022-12-31-$180.00K
10-K · filed 2024-04-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
Rocket One Inc. (RKTO)United States$0.019B
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
NextCure, Inc. (NXTC)United States$0.024B-0.15
Biofrontera Inc. (BFRI)United States$0.018B-2.13